IDH inhibitors may be an effective and manageable treatment for rare tumors with usually poor prognosis (e.g., SNUCs [141]) but also an alternative treatment in diseases where standard treatments may have a heavy burden of morbidities (such as radiotherapy-related cognitive impairment for gliomas). Here, IDH2 is linked to glioma.